KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference
Aug 03, 2017 11:30 am UTC| Business
CORALVILLE, Iowa, Aug. 03, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and...
Aug 03, 2017 11:30 am UTC| Business
IRVINE, Calif., Aug. 03, 2017 -- Identillect Technologies Corp. (the "Company" or "Identillect") (TSX-V:ID) (OTCQB:IDTLF) (Frankfurt:8ID), announces today that the law firm Lounsbery, Ferguson, Altona Peak LLP (LFAP)...
MGP Ingredients Reports Second Quarter 2017 Results
Aug 03, 2017 11:30 am UTC| Business
ATCHISON, Kan., Aug. 03, 2017 -- MGP Ingredients, Inc. (Nasdaq:MGPI), a leading supplier of premium distilled spirits and specialty wheat proteins and starches, today reported results for the second quarter ended June...
ReWalk Robotics Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:30 am UTC| Business
-- 146% YOY growth in Q2 revenue to $2 million and record 1H revenue of $4.5 million – -- 11 favorable commercial case-by-case insurance coverage decisions -- -- 217 pending insurance claims in the U.S. and Germany -- --...
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
Aug 03, 2017 11:30 am UTC| Business
On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in...
DIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
Aug 03, 2017 11:30 am UTC| Business
DIA is a professional community and knowledge exchange network for global health care product developmentMr. Roberts, who is also the Chief Operating Officer and EVP of Finance at Cancer Genetics, Inc. (Nasdaq:CGIX) will...
Adaptimmune Reports Second Quarter 2017 Financial Results
Aug 03, 2017 11:30 am UTC| Business
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 – – Enrolling 9 clinical studies with NY-ESO as well...